Global Head and Neck Cancer Therapeutics Market Report 2022: Historical Data 2017-2020, Base year of 2021, Estimates for 2022, & Forecasts 2023-2027
May 20, 2022 04:38 ET | Research and Markets
Dublin, May 20, 2022 (GLOBE NEWSWIRE) -- The "Global Head and Neck Cancer Therapeutics Market, By Type (Diagnostic Methods v/s Treatment Type), By Treatment Type (By Disease Indication, By Route of...
7 Hills Logo.png
New Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors
May 18, 2022 19:23 ET | 7 Hills Pharma
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), together with The University of Texas MD Anderson Cancer Center (“MD Anderson”) and Texas Heart Institute (“THI”),...
Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors
May 18, 2022 07:00 ET | https://immatics.com/
The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab1, a PD-1 immune checkpoint...
Immatics behandelt ersten Patienten mit ACTengine® TCR-T-Zelltherapie IMA203 in Kombination mit Checkpoint-Inhibitor Opdivo® (Nivolumab) in Patienten mit fortgeschrittenen soliden Tumoren
May 18, 2022 07:00 ET | Immatics N.V.
Die Phase-1b-Dosis-Expansionskohorte untersucht die Sicherheit, biologische Aktivität und erste Anzeichen einer Anti-Tumor-Aktivität der IMA203 TCR-T-Zelltherapie gegen die Zielstruktur PRAME in...
Affimed Logo.jpg
Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity
May 16, 2022 08:00 ET | Affimed N.V.
Correlative science data from AFM24-101 clinical study support the rationale to develop AFM24 as monotherapy and in combination therapiesFirst preclinical data set on the combination of AFM28 with...
Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update
May 12, 2022 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
Affimed Logo.jpg
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
May 12, 2022 10:31 ET | Affimed N.V.
The novel bispecific innate cell engager AFM28 stimulates NK cells to destroy CD123-positive tumor cells via antibody-dependent cellular cytotoxicity.AFM28 induces effective lysis of hematological...
Oncology Market Trends 2022 | North America, Europe, & APAC Industry Forecasts 2028: Graphical Research
May 12, 2022 08:00 ET | Graphical Research
Pune, India, May 12, 2022 (GLOBE NEWSWIRE) -- The global oncology market size is anticipated to rise substantially through 2028, attributed to the rising incidence of cancer across many regions...
Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 10, 2022 07:30 ET | Sensei Biotherapeutics
- SNS-101 preclinical data provide encouraging validation of pH-sensitive approach to inhibiting VISTA with high selectivity to treat solid tumors - - Cash runway extended into the first quarter of...
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors
May 10, 2022 07:00 ET | https://immatics.com/
Patient enrollment for IMA401 Phase 1 trial started at first clinical site in GermanyThe study will evaluate safety, tolerability, and initial anti-tumor activity of IMA401 in patients with recurrent...